This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) November 18, 2022
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at https://t.co/HxTcVC3PtH pic.twitter.com/y7o71HUPiZ
Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
